Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Durogesic® (fentanyl transdermal drug delivery system), TTS-fentanyl
Durogesic · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Durogesic® (fentanyl transdermal drug delivery system) | DRUG | - |
Inclusion Criteria: * Patients with a confirmed malignancy (whose pain is judged by the investigator to be caused by the malignancy), or patients with other life-threatening/terminal disease whose pain requires treatment with strong opioid analgesia * requiring treatment of pain with a strong opioi...
Top 4 of 15 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Eli Lilly and Company | LLY | 4 | PHASE3 | Retatrutide, LY3016859, LY3556050, LY3526318, LY3857210 |
| Fortress Biotech, Inc. | FBIO | 1 | PHASE3 | Tramadol |
| Merck & Co., Inc. | MRK | 1 | PHASE2 | MK-6916 |
| Creative Medical Technology Holdings, Inc. | CELZ | 1 | PHASE1 | CELZ-201-DDT |
Durogesic is a fentanyl transdermal drug delivery system, a small molecule therapy developed by Johnson & Johnson for the treatment of chronic pain. It delivers fentanyl through the skin as a patch for long-term narcotic pain relief therapy. It is also known as Durogesic (fentanyl transdermal drug delivery system).
Durogesic is used for chronic pain requiring long-term narcotic pain relief therapy. It is a fentanyl transdermal patch studied in patients with chronic pain, including a pediatric population aged 2 years and older. The therapeutic area is pain management.
Durogesic is developed by Johnson & Johnson, which trades under the ticker JNJ. The company is the developer of the fentanyl transdermal drug delivery system.
Durogesic has been studied in Phase 3 clinical development. It is an investigational asset in the chronic pain therapeutic area, and the Phase 3 trial evaluating it has been completed.
Durogesic was evaluated in one completed Phase 3 trial, NCT00271453, titled a study to assess the safety and effectiveness of Durogesic (fentanyl transdermal patch) in the treatment of children with chronic pain requiring long-term narcotic pain relief therapy. The trial enrolled 41 participants aged 2 years and older.
Yes, Durogesic is also known as Durogesic (fentanyl transdermal drug delivery system). The two names refer to the same product, a fentanyl transdermal patch developed by Johnson & Johnson for chronic pain.